drugset / Trial / NCT05828303
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.
Timeline
- Start
- 2024-11-15
- Primary completion
- 2025-07-31
- Completion
- 2025-11-30
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | Metformin | Small molecule | — | Oral |
| Subject | Repotrectinib | Small molecule | — | Oral |
| Subject | Rosuvastatin | Small molecule | — | Oral |